Warp speed: The government initiative aims to provide 300 million doses of a Covid-19 vaccine by January 2021.
Other OWS vaccine dose deals so far include $ 1.95 billion in Pfizer for 100 million doses, up to $ 1.2 billion in AstraZeneca for 300 million doses and other development work, and $ 1.6 billion to Novavax for 100 million doses.
What’s next: Sanofi and GSK expect to start an early clinical trial with the vaccine in September, followed by a final Phase III study towards the end of the year. If the results are positive, the companies plan to seek approval from the Food and Drug Administration in the first half of 2021.
Sanofi and GSK are also scaling up production and plan to produce up to a billion doses per year worldwide.